Popular Articles

Chalenges Faced By HIV Patients Living Longer Lives Due To New Therapies
New HIV therapies have prolonged lives and improved health for patients with HIV, but the treatments have also brought the longer-term effects of the disease into sharper focus.
generic viagra online
Attorney General Martha Coakley's Office Reaches $22 Million Medicaid Fraud Settelement From Eli Lilly
Massachusetts Attorney General Martha Coakley"s Office has reached an agreement with pharmaceutical manufacturer Eli Lilly & Co. ("Lilly"), resolving allegations that the company engaged in the improper marketing of its atypical antipsychotic drug, Zyprexa. Under the terms of the settlement, Lilly has paid $22,499,433.04 to the Massachusetts Medicaid Program, which provides funds for health care products and services to eligible low-income individuals, including people with disabilities, children and elder citizens.
News of the day
Abraxis Bioscience Completes Enrollment Of Pivotal Phase III Advanced Lung Cancer Study Evaluating Abraxane(R) Vs. Taxol(R)
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced that the company has completed patient enrollment of a pivotal, phase III clinical study comparing the company"s chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) with Taxol® (paclitaxel) injection, both in combination with carboplatin, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The study, which is being conducted at 111 sites globally, includes 1,050 patients and is being led by principal investigator Dr. Mark Socinski at the University of North Carolina Lineberger Comprehensive Cancer Center. It is one of the largest NSCLC clinical studies to complete enrollment.
Cardiovascular

TAU Develops Tiny Device To "Sniff Out" Disease, Heart Attacks, Poison And Environmental Pollution

Like the sensitive seismographs that can pick up tremors of impending earthquakes long before they strike, a similar invention from Tel Aviv University researchers may change the face of molecular biology. Coupling biological materials with an electrode-based device, Prof. Judith Rishpon of TAU"s Department of Molecular Microbiology and Biotechnology is able to quickly and precisely detect pathogens and pollution in the environment - and infinitesimally small amounts of disease biomarkers in our blood. About the size of a stick of gum, the new invention may be applied to a wide range of environments and situations. The aim is for the device to be disposable and cost about $1. "Biosensors are important for the bio-terror industry, but are also critical for detecting pathogens in water, for the food industry, and in medical diagnostics," says Prof. Rishpon. Her latest research appeared in the journals Nanomedicine: Nanotechnology Biology and Medicine, Electroanalysis and Bioelectrochemistry. Portable and precise What makes this particular invention particularly appealing is its small size and the fact that it can be easily connected to a handheld device like a Blackberry or iPhone for quick and reliable results. An electrical signal will pulse "yes" for the presence of a test molecule and a "no" for its absence. Currently, clinical researchers are testing its application in cancer diagnostics, focusing on the detection of proteins associated with colon and brain cancer and efficacy of anticancer drugs. But the device is capable of detecting various types of substances. "It really depends on what you put at the end of the electrode," says Prof. Rishpon. "You can put enzymes, antibodies or bacteria on my electrodes to sense the existence of a chemical target. Then we can measure the amount of the target, assessing its potency by using additional enzymes or by looking at the changes of the electrochemical properties on the device," she says. An early warning system for heart attacks Enzymes released before the onset of a heart attack can also be detected, so this application has obvious uses in an operating room to give a physician warning of an impending attack during a procedure. It could be fitted into an implant like a pacemaker or another future device to alert the user to impending dangers, thus preventing sudden death. Prof. Rishpon is also investigating the application of her technology to detect for pathogens in drinking water such as estrogen, a byproduct of the female birth control pill. The presence of these chemicals in America"s drinking water is no minor health concern. And before tackling the problem, water officials need to know what they are up against. Prof. Rishpon"s solution could be part of the future toolkit, she believes. A bio-watchdog for the organic food industry Detecting pesticides in food is another very desirable application. The organic food market is calling for more rigorous testing and regulations to ensure spraying doesn"t occur on some farms, and that limits are not breached on others. Commercial applications of Prof. Rishpon"s basic research are already underway in many areas of diagnostics, but clearly there are more to come. "My super sensors are cheap, accurate and highly sensitive, and in principle they could detect and measure the presence of almost every biological-based material," Dr. Rishpon concludes. She is also collaborating on the device with scientists at Arizona State University. George Hunka American Friends of Tel Aviv University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):